Fumaric acid amides

Details Fumaric acid amides Fumaric acid amides

2006-05-31

2008-10-07

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S345000

Reexamination Certificate

active

07432240

ABSTRACT:
Fumaric acid amides of the general formula (I)wherein R1represents OR3or a D- or L-amino acid radical —NH—CHR4—COOH bonded via an amide bond, wherein R3is hydrogen, a straight-chained or branched, optionally substituted C1-24alkyl radical, a phenyl radical or C6-10aralkyl radical and R4is a side chain of a natural or synthetic amino acid and R2represents a D- or L-amino acid radical —NH—CHR5—COOH bonded via an amide bond or a peptide radical comprising 2 to 100 amino acids bonded via an amide bond, wherein R5is a side chain of a natural or synthetic amino acid, are used for preparing a drug (1) for the therapy of an autoimmune disease; (2) for use in transplantation medicine; (3) for the therapy of mitochondrial diseases; or (4) for the therapy of NF-kappaB mediated diseases.

REFERENCES:
patent: 2993837 (1961-07-01), Millar et al.
patent: 3832287 (1974-08-01), Gale et al.
patent: 4515974 (1985-05-01), Zecher et al.
patent: 4746668 (1988-05-01), Sato et al.
patent: 4851439 (1989-07-01), Speiser et al.
patent: 4959389 (1990-09-01), Speiser et al.
patent: 5149695 (1992-09-01), Speiser et al.
patent: 5214196 (1993-05-01), Blank
patent: 5242905 (1993-09-01), Blank
patent: 5350741 (1994-09-01), Takada
patent: 5359128 (1994-10-01), Blank
patent: 5424332 (1995-06-01), Speiser et al.
patent: 5451667 (1995-09-01), Speiser et al.
patent: 5538968 (1996-07-01), Chiesi et al.
patent: 5548059 (1996-08-01), Bayley et al.
patent: 5569742 (1996-10-01), Kirby et al.
patent: 5589504 (1996-12-01), Dannenberg et al.
patent: 5763408 (1998-06-01), Nishikawa et al.
patent: 5972363 (1999-10-01), Clikeman et al.
patent: 6277882 (2001-08-01), Joshi et al.
patent: 6355676 (2002-03-01), Joshi et al.
patent: 6359003 (2002-03-01), Joshi et al.
patent: 6436992 (2002-08-01), Joshi et al.
patent: 6509376 (2003-01-01), Joshi et al.
patent: 6858750 (2005-02-01), Joshi et al.
patent: 9921593 (1999-10-01), None
patent: 2248955 (1998-11-01), None
patent: 25 30 372 (1977-01-01), None
patent: 26 21 214 (1977-11-01), None
patent: 38 34 794 (1990-04-01), None
patent: 103 274 (1984-03-01), None
patent: 1 216 699 (1970-12-01), None
patent: 1 422 726 (1976-01-01), None
patent: WO 89/01930 (1989-03-01), None
patent: WO 94/28883 (1994-12-01), None
patent: WO 95/25102 (1995-09-01), None
patent: WO 96/02244 (1996-02-01), None
patent: WO 96/27369 (1996-09-01), None
patent: WO 97/48400 (1997-12-01), None
patent: WO 98/04290 (1998-02-01), None
patent: WO 98/27970 (1998-07-01), None
patent: WO 98/52549 (1998-11-01), None
patent: WO 99/21565 (1999-05-01), None
patent: WO 2005/023241 (2005-03-01), None
R. Andruszkiewicz et al. J. Med. Chem. (1990) 33(1), pp. 132-135.
Aiache, J. et al., J. Pharm. Biomed. Anal 8(6): 499-506 (1990).
Altmeyer, P. et al., “Systemische Therapie der Psoriasis”, T & E Derm. Jg., vol. 27, pp. 380-382, 384, 1997.
Amamoto, T. et al. “Effect of E-64, Thiol Protease Inhibitor on the Secondary Anti-SRBC Response In-Vitro”, Microbiol. Immunol., vol. 28(1), pp. 85-97, 1984.
Bacharach-Buhles, M. et al., “Fumaric Acid Esters (FAEs) Suppress CD-15-and ODP 4-positive Cells in Psoriasis”, Acta. Derm. Venerol., suppl. 186, pp. 79-82, 1994.
Barrett, A. J. at al., “L-trans-Epoxysuccinyl-leucylmido (4-guanidino) butane and its analogues as inhibitors of cysteine proteinases including cathepains B,H, and L”, Biochem. J., vol. 201, pp. 189-198, 1982.
Bayard, W. et al., “Peroral long term treatment of psoriasis using fumaric acid derivatives”, Der Hautarzt, vol. 38(5), pp. 279-285, Medline Abstract, 1987.
Bellier, B. et al., “Replacement of Glycine with Dicarbonyl and Related Moieties in Analogues of the C-Terminal Pentapeptide of Cholecystokinin:CCK4Agonists Displaying a Novel Binding Mode”, J. Med. Chem., vol. 43, pp. 3614-3623, 2000.
Birch, A.J. et al., “Metabolites of Aspergillus Indicus: The Structure and Some Aspects of the Biosynthesis of Dihydrocanadensolide”, Aust. J. Chem., vol. 21, pp. 2775-2784, 1968.
Choo, H-Y et al., “Design and Synthesis of alpha, beta-unsaturated Carbonyl Compounds as Potential ACE Inhibitors”, Eur. J. Med. Chem., vol. 35, pp. 643-648, 2000.
Co-pending U.S. Appl. No. 10/148,858, filed Dec. 11, 2000; Inventors: Rajendra Joshi et al.
Co-pending U.S. Appl. No. 10/250,983, filed Jan. 8, 2002; Inventors: Rajendra Joshi et al.
Dethlefsen, L. A. et al., Toxic Effects of Acute Glutathione Depletion by Buthionine Sulfoximine and Dimethylfumarate on Murine Mammary Carcinoma Cells, Radiation Res., vol. 114, pp. 215-224, 1988.
Galpin, I.J. et al., “The Synthesis of an Insulin Active Site Analogue”, Tetrahedron, vol. 39(1), pp. 149-158, 1983.
Gasser et al., “Host vs Graft and Graft vs. Host Reactions After Allogeneic Heterotopic Small Bowel Transplantation in the Rat”, Transplantation Proc., vol. 24(3), pp. 1128-1129, 1992.
Gerhard, U. et al., “The Free Energy Change of Restricting a Bond Rotation in the Binding of Peptide Analogues to Vancomycin Group Antibiotics”, Bioorgan. & Med. Chem. Letters, vol. 3(5), pp. 803-808, 1993.
Gordon, G.B. et al., “Induction of NAD(P)H:quinone reductase in human peripheral blood lymphocytes”, Carcinogenesis, vol. 12(12), pp. 2393-2395, 1991.
Griehl, C. et al., “alpha-Aspartyl Peptides by Addition of Amines to N-Malsylamino Acid Derivatives”, Chem. Of Peptides and Proteins, vol. 5(6), pp. 99-103, 1993.
Hildebrandt, H., “Pschryembel Klinisches Woerterbuch Ed. 258”, Walter de Gruyter, p. 182, col. 1 para. 2, and p. 1469, col. 1 para. 16-col. 2, para. 1, 1998.
Hohenegger, M. et al., “Nephrotoxicity of Fumaric Acid Monoethylester (FA ME)”, Adv. In Exp. Med. And Biol., vol. 252, pp. 265-272, 1989.
Holroyd, S.E. et al., “Rational Design and Binding of Modified Cell-Wall Peptides to vancomycin-Group Antibiotic: Factorising Free Energy Contributions to Binding”, Tetrahedron, vol. 49(41), pp. 9171-9182, 1993.
Hunziker, T. et al., “Is Psoriasis an Autoimmune Disease?”, excerpt from “Therapeutische Umschau”, Derm. Clinic of Univ. Berne, vol. 50 (2nd Ed.), pp. 110-113, translated ver. 5 pgs., 1993.
Immun. Durch Fumaderm, das richtungsweise Konzept, Charité-Berlin Symposium 1-3, 28 pages, 4 page translation of pp. 23-24, 1996.
International Search Report for PCT/EP02/00107 dated Aug. 1, 2003 (Priority Application for U.S. Appl. No. 10/433,295).
Kamiyama, T. et al., “Ro 09-1679, A Novel Thrombin Inhibitor”, Jour, of Antibiotics, vo. 45(3), pp. 424-427, 1992.
Krstenansky, J.L. et al., “Development of MDL 28,050, a Small Stable Antithrombin Agent Based on a Functional Domain of the Leech Protein, Hirudin”, Thrombosis and Haemostasis, vol. 63(2), 1990.
Kuroda, K. et al., “Fumaric Acid Enhances DNA Synthesis of Rat Hepatocytes by Counter Acting the Toxicities of Mitomycin C and Aflatoxin B”, Jpn. J. Cancer Res., vol. 77, pp. 750-758, 1986.
Kuroda, K. et al., “Inhibitory Effect of capsella-bursa-pastoris Extract ion Growth of Ehrlich Solid Tumor in Mice”, Cancer Research, vol. 36, Abstract only, 1976.
Langlois, M. et al., “Synthesis of symmetrical pseudopeptides as potential inhibitors of the human immunodeficiency virus-I protease”, Eur. J. Med. Chem., vol. 29, pp. 639-647, 1994.
Lehnert, S. et al., “Radiation response of Drug-Resistant Variants of a Human Breast Cancer Cell Line: The Effect of Glutathione Depletion”, Radiation Research, vol. 142, pp. 208-215, 1990.
Merck Manual, Merck XP-002141006, p. 327, para. 2-para. 6, 1987.
Miller, A.C. et al., “Posttranscriptional Down-Regulation of ras Oncogene Expression by Inhibitors of Cellular Glutathione”, Mol. And Cell. Biol., vol. 13(7), pp. 4416-4422, 1993.
Mrowietz, U., “Nephrotoxische Wirkung durch Fumarsauere”, Hautartzt, vol. 51, p. 615, 2000.
Murthy, K. et al., J. Pharm. Sci. 82(2): 113-126 (1993).
Nathens et al., “Th

Affiliated with

Also associated with

Rating

Fumaric acid amides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fumaric acid amides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fumaric acid amides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3994492